REVB
Revelation Biosciences, Inc.
Price Chart
Latest Quote
$0.98
-0.09 (-8.41%)
Current Price
| Previous Close | $1.07 |
| Open | $1.08 |
| Day High | $1.09 |
| Day Low | $0.98 |
| Volume | 66,385 |
Stock Information
| Shares Outstanding | 3.91M |
| Total Debt | $759K |
| Cash Equivalents | $14.11M |
| Net Income | $-21.50M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $3.83M |
| EPS (TTM) | $-1.27 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $-9.52M |
| Income | $-21.50M |
| Book/sh | $3.32 |
| Cash/sh | $3.61 |
| Employees | 8 |
Financial Ratios
| Quick Ratio | 9.96 |
| Current Ratio | 10.02 |
| Debt/Eq | 5.84 |
Returns & Margins
| ROA | -66.19% |
| ROE | -124.41% |
Ownership
| Insider Ownership | 4.79% |
| Institutional Ownership | 12.78% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -0.35 |
| P/B | 0.29 |
Analyst Data
| Recommendation | none |
| Target Price | $19.25 |
Technical Indicators
| SMA20 | $1.04 |
| SMA50 | $1.08 |
| SMA200 | $3.05 |
| RSI | 37.58 |
| ATR | 0.0639 |
| Shares Float | 3.44M |
| Short Float | 0.70% |
| Short Ratio | 0.45 |
| Volatility | -0.10 |
| Rel Volume | 1.43 |
Performance History
| Week | -2.97% |
| Month | -4.85% |
| Quarter | -18.33% |
| 6 Months | -75.08% |
| YTD | -69.86% |
| Year | -89.66% |
| 3 Years | -99.98% |
| 5 Years | -100.00% |
| 10 Years | -100.00% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $0.98 | 66,200 |
| 2026-06-17 | $1.07 | 110,800 |
| 2026-06-16 | $0.96 | 31,000 |
| 2026-06-15 | $0.99 | 89,400 |
| 2026-06-12 | $1.00 | 36,100 |
| 2026-06-11 | $1.01 | 23,500 |
| 2026-06-10 | $1.03 | 37,500 |
| 2026-06-09 | $1.04 | 49,000 |
| 2026-06-08 | $1.01 | 23,100 |
| 2026-06-05 | $0.99 | 108,300 |
| 2026-06-04 | $1.05 | 36,000 |
| 2026-06-03 | $1.04 | 69,300 |
| 2026-06-02 | $1.06 | 52,400 |
| 2026-06-01 | $1.09 | 32,400 |
| 2026-05-29 | $1.10 | 35,100 |
| 2026-05-28 | $1.10 | 32,000 |
| 2026-05-27 | $1.09 | 47,400 |
| 2026-05-26 | $1.06 | 9,600 |
| 2026-05-22 | $1.07 | 16,100 |
| 2026-05-21 | $1.08 | 18,000 |
| 2026-05-20 | $1.09 | 31,400 |
| 2026-05-19 | $1.03 | 23,100 |
About Revelation Biosciences, Inc.
Revelation Biosciences, Inc. operates as a clinical-stage life science company that focuses on the rebalancing inflammation to optimize health. The company's lead product candidate is lead product candidate Gemini, a proprietary formulation platform of phosphorylated hexaacyl disaccharide (PHAD), an established Toll-like receptor 4 (TLR) agonist that works by modulating and rebalancing a dysregulated inflammatory response. It also engages in the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system, including GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was formerly known as Petra Acquisition, Inc. and changed its name to Revelation Biosciences, Inc. in January 2022. Revelation Biosciences, Inc. was incorporated in 2019 and is based in San Diego, California.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $9,070,814 | $7,975,109 | $8,656,664 | $10,864,511 |
| Other Income Expense | $157,165 | $-7,063,427 | $8,536,410 | $34,962 |
| Other Non Operating Income Expenses | $155,007 | $-7,144,868 | $207,473 | $34,962 |
| Operating Expense | $9,070,814 | $7,975,109 | $8,656,664 | $10,864,511 |
| General And Administrative Expense | $5,006,957 | $4,426,113 | $4,510,762 | $5,487,111 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-8,913,649 | $-15,038,536 | $-120,254 | $-10,829,549 |
| Normalized Income | $-8,915,807 | $-15,119,977 | $-8,449,191 | $-10,829,549 |
| Net Income From Continuing And Discontinued Operation | $-8,913,649 | $-15,038,536 | $-120,254 | $-10,829,549 |
| Total Operating Income As Reported | $-9,070,814 | $-7,975,109 | $-8,656,664 | $-10,864,511 |
| Net Income Common Stockholders | $-14,865,177 | $-15,038,536 | $-120,254 | $-10,829,549 |
| Net Income | $-8,913,649 | $-15,038,536 | $-120,254 | $-10,829,549 |
| Net Income Including Noncontrolling Interests | $-8,913,649 | $-15,038,536 | $-120,254 | $-10,829,549 |
| Net Income Continuous Operations | $-8,913,649 | $-15,038,536 | $-120,254 | $-10,829,549 |
| Pretax Income | $-8,913,649 | $-15,038,536 | $-120,254 | $-10,829,549 |
| Operating Income | $-9,070,814 | $-7,975,109 | $-8,656,664 | $-10,864,511 |
| Per Share | ||||
| Diluted EPS | $-23.95 | $-1052.16 | $-101.28 | $-91775.84 |
| Basic EPS | $-23.95 | $-1052.16 | $-101.28 | $-91775.84 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-9,045,914 | $-8,028,627 | $-16,960,552 | $-10,839,463 |
| Total Unusual Items | $2,158 | $81,441 | $8,328,937 | - |
| Total Unusual Items Excluding Goodwill | $2,158 | $81,441 | $8,328,937 | - |
| Reconciled Depreciation | $27,058 | $27,923 | $25,049 | $25,048 |
| EBITDA (Bullshit earnings) | $-9,043,756 | $-7,947,186 | $-8,631,615 | $-10,839,463 |
| EBIT | $-9,070,814 | $-7,975,109 | $-8,656,664 | $-10,864,511 |
| Diluted Average Shares | $620,785 | $14,292 | $1,187 | $118 |
| Basic Average Shares | $620,785 | $14,292 | $1,187 | $118 |
| Diluted NI Availto Com Stockholders | $-14,865,177 | $-15,038,536 | $-120,254 | $-10,829,549 |
| Otherunder Preferred Stock Dividend | $5,951,528 | $0 | - | - |
| Gain On Sale Of Security | $2,158 | $81,441 | $8,328,937 | - |
| Research And Development | $4,063,857 | $3,548,996 | $4,145,902 | $5,377,400 |
| Selling General And Administration | $5,006,957 | $4,426,113 | $4,510,762 | $5,487,111 |
| Other Gand A | $1,960,989 | $1,657,511 | $2,238,757 | $3,612,405 |
| Salaries And Wages | $3,045,968 | $2,768,602 | $2,272,005 | $1,874,706 |
Fetched: 2026-06-17
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $8,860,995 | $4,708,382 | $6,647,715 | $1,052,453 |
| Total Assets | $11,582,924 | $6,622,049 | $12,212,609 | $5,503,415 |
| Total Non Current Assets | $771,296 | $56,332 | $65,084 | $90,133 |
| Other Non Current Assets | $30,941 | - | - | - |
| Current Assets | $10,811,628 | $6,565,717 | $12,147,525 | $5,413,282 |
| Other Current Assets | $33,948 | $49,501 | $29,476 | $73,132 |
| Prepaid Assets | $77,349 | $17,198 | $55,215 | $0 |
| Cash Cash Equivalents And Short Term Investments | $10,700,331 | $6,499,018 | $11,991,701 | $5,252,979 |
| Cash And Cash Equivalents | $10,700,331 | $6,499,018 | $11,991,701 | $5,252,979 |
| Current Deferred Assets | - | $0 | $71,133 | $87,171 |
| Debt | ||||
| Total Debt | $746,784 | $0 | - | $0 |
| Long Term Debt And Capital Lease Obligation | $723,771 | $0 | - | - |
| Current Debt And Capital Lease Obligation | $23,013 | - | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $2,721,929 | $1,913,667 | $5,564,894 | $4,450,962 |
| Total Non Current Liabilities Net Minority Interest | $723,771 | $0 | $0 | $0 |
| Current Liabilities | $1,998,158 | $1,913,667 | $5,564,894 | $4,450,962 |
| Payables And Accrued Expenses | $1,975,145 | $1,913,667 | $2,512,358 | $1,539,702 |
| Payables | $577,501 | $783,621 | $1,359,898 | $554,205 |
| Accounts Payable | $577,501 | $783,621 | $1,359,898 | $554,205 |
| Other Current Liabilities | - | $2,246 | $141,276 | - |
| Current Deferred Liabilities | - | $0 | $2,911,260 | $2,911,260 |
| Equity | ||||
| Common Stock Equity | $8,860,995 | $4,708,382 | $6,647,715 | $1,052,453 |
| Total Equity Gross Minority Interest | $8,860,995 | $4,708,382 | $6,647,715 | $1,052,453 |
| Stockholders Equity | $8,860,995 | $4,708,382 | $6,647,715 | $1,052,453 |
| Retained Earnings | $-49,419,287 | $-40,505,638 | $-25,467,102 | $-25,346,848 |
| Preferred Stock Equity | - | - | - | - |
| Other | ||||
| Ordinary Shares Number | $1,583,969 | $43,518 | $1,377 | $118 |
| Share Issued | $1,583,969 | $43,518 | $1,377 | $118 |
| Tangible Book Value | $8,860,995 | $4,708,382 | $6,647,715 | $1,052,453 |
| Invested Capital | $8,860,995 | $4,708,382 | $6,647,715 | $1,052,453 |
| Working Capital | $8,813,470 | $4,652,050 | $6,582,631 | $962,320 |
| Capital Lease Obligations | $746,784 | $0 | - | $0 |
| Total Capitalization | $8,860,995 | $4,708,382 | $6,647,715 | $1,052,453 |
| Additional Paid In Capital | $58,278,698 | $45,213,976 | $32,114,801 | $26,399,224 |
| Capital Stock | $1,584 | $44 | $16 | $77 |
| Common Stock | $1,584 | $44 | $16 | $77 |
| Long Term Capital Lease Obligation | $723,771 | $0 | - | - |
| Current Capital Lease Obligation | $23,013 | $0 | - | $0 |
| Current Accrued Expenses | $1,397,644 | $1,130,046 | $1,152,460 | $985,497 |
| Net PPE | $740,355 | $56,332 | $65,084 | $90,133 |
| Accumulated Depreciation | $-98,988 | $-94,802 | $-66,879 | $-41,830 |
| Gross PPE | $839,343 | $151,134 | $131,963 | $131,963 |
| Other Properties | $839,343 | $151,134 | $131,963 | $131,963 |
| Preferred Stock | - | $0 | $0 | $0 |
Fetched: 2026-06-17
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-8,269,581 | $-18,340,447 | $-7,286,286 | $-11,219,396 |
| Operating Activities | ||||
| Operating Cash Flow | $-8,269,581 | $-18,321,276 | $-7,286,286 | $-11,219,396 |
| Cash Flow From Continuing Operating Activities | $-8,269,581 | $-18,321,276 | $-7,286,286 | $-11,219,396 |
| Operating Gains Losses | $9,049 | $-81,441 | $-8,328,937 | - |
| Investing Activities | ||||
| Investing Cash Flow | $0 | $-19,171 | $0 | $0 |
| Cash Flow From Continuing Investing Activities | $0 | $-19,171 | $0 | $0 |
| Capital Expenditure | - | $-19,171 | - | - |
| Financing Activities | ||||
| Issuance Of Capital Stock | $3,388,244 | $5,417,053 | $14,029,974 | $4,456,048 |
| Financing Cash Flow | $12,470,894 | $12,847,764 | $14,025,008 | $15,197,646 |
| Cash Flow From Continuing Financing Activities | $12,470,894 | $12,847,764 | $14,025,008 | $15,197,646 |
| Net Common Stock Issuance | $3,388,244 | $5,417,053 | $14,029,974 | $4,451,048 |
| Common Stock Issuance | $3,388,244 | $5,417,053 | $14,029,974 | $4,451,048 |
| Repurchase Of Capital Stock | - | $0 | $-5,000 | - |
| Net Preferred Stock Issuance | - | $0 | $-5,000 | $5,000 |
| Net Other Financing Charges | - | - | - | $11,533,393 |
| Preferred Stock Issuance | - | - | - | $5,000 |
| Other | ||||
| End Cash Position | $10,700,331 | $6,499,018 | $11,991,701 | $5,252,979 |
| Beginning Cash Position | $6,499,018 | $11,991,701 | $5,252,979 | $1,274,729 |
| Changes In Cash | $4,201,313 | $-5,492,683 | $6,738,722 | $3,978,250 |
| Proceeds From Stock Option Exercised | $9,082,650 | $7,430,711 | $34 | $5,087 |
| Net PPE Purchase And Sale | $0 | $-19,171 | $0 | $0 |
| Purchase Of PPE | $0 | $-19,171 | $0 | $0 |
| Change In Working Capital | $-6,037 | $-3,423,072 | $982,135 | $-730,971 |
| Change In Other Current Liabilities | $5,866 | $0 | $0 | $-16,752 |
| Change In Other Current Assets | $-30,941 | $0 | - | - |
| Change In Payables And Accrued Expense | $63,636 | $-3,512,197 | $911,623 | $-1,222,109 |
| Change In Accrued Expense | $269,756 | $-2,935,920 | $161,963 | $-556,067 |
| Change In Payable | $-206,120 | $-576,277 | $749,660 | $-666,042 |
| Change In Account Payable | $-206,120 | $-576,277 | $749,660 | $-666,042 |
| Change In Prepaid Assets | $-44,598 | $17,992 | $-11,559 | $569,044 |
| Other Non Cash Items | $18,630 | $25,000 | - | $14,960 |
| Stock Based Compensation | $595,368 | $168,850 | $155,721 | $301,116 |
| Depreciation Amortization Depletion | $27,058 | $27,923 | $25,049 | $25,048 |
| Depreciation And Amortization | $27,058 | $27,923 | $25,049 | $25,048 |
| Depreciation | $27,058 | $27,923 | $25,049 | $25,048 |
| Gain Loss On Investment Securities | $-2,158 | $-81,441 | $-8,328,937 | - |
| Gain Loss On Sale Of PPE | $11,207 | $0 | - | - |
| Net Income From Continuing Operations | $-8,913,649 | $-15,038,536 | $-120,254 | $-10,829,549 |
| Preferred Stock Payments | - | $0 | $-5,000 | - |
| Change In Other Working Capital | - | $71,133 | $82,071 | $-61,154 |
| Repayment Of Debt | - | - | $0 | $-3,296,882 |
| Issuance Of Debt | - | - | $0 | $2,500,000 |
| Net Issuance Payments Of Debt | - | - | $0 | $-796,882 |
| Net Short Term Debt Issuance | - | - | $0 | $-796,882 |
| Short Term Debt Payments | - | - | $0 | $-3,296,882 |
| Short Term Debt Issuance | - | - | $0 | $2,500,000 |
| Change In Interest Payable | - | - | $0 | $36,920 |
Fetched: 2026-06-17